Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne

Duchenne Muscular Dystrophy (DMD) is a severe muscle disorder caused by lack of dystrophin. Predictive biomarkers able to anticipate response to the therapeutic treatments aiming at dystrophin re-expression are lacking. The objective of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomarker for Duchenne. Two natural history cohorts were studied including 168 longitudinal samples belonging to 66 patients. We further studied 1536 samples obtained from 3 independent clinical trials with drisapersen, an antisense oligonucleotide targeting exon 51: an open label study including 12 patients; a phase 3 randomized, double blind, placebo controlled study involving 186 patients; an open label extension study performed after the phase 3. Analysis of natural history cohorts showed elevated MMP-9 levels in patients and a significant increase over time in longitudinal samples. MMP-9 decreased in parallel to clinical stabilization in the 12 patients involved in the open label study. The phase 3 study and subsequent extension study clarified that the decrease in MMP-9 levels was not predictive of treatment response. These data do not support the inclusion of serum MMP-9 as predictive biomarker for DMD patients.

[1]  E. Bakker,et al.  An urgent need for a change in policy revealed by a study on prenatal testing for Duchenne muscular dystrophy , 2012, European Journal of Human Genetics.

[2]  J. Mendell,et al.  Dystrophin immunity in Duchenne's muscular dystrophy. , 2010, The New England journal of medicine.

[3]  I. Graham,et al.  Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. , 2007, Human gene therapy.

[4]  R. Finkel,et al.  Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy , 2013, PloS one.

[5]  D. Wagner,et al.  Plasma storage at −80 °C does not protect matrix metalloproteinase-9 from degradation , 2005 .

[6]  J. Tanus-Santos,et al.  Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. , 2008, Analytical biochemistry.

[7]  H. Methe,et al.  Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. , 2010, The American journal of cardiology.

[8]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[9]  D. Wagner,et al.  Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. , 2005, Analytical biochemistry.

[10]  F. Baas,et al.  Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. , 2003, Human molecular genetics.

[11]  S. Peltz,et al.  THE 6-MINUTE WALK TEST AND OTHER CLINICAL ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: RELIABILITY, CONCURRENT VALIDITY, AND MINIMAL CLINICALLY IMPORTANT DIFFERENCES FROM A MULTICENTER STUDY , 2013, Muscle & nerve.

[12]  E. Bertini,et al.  Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies , 2014, EMBO molecular medicine.

[13]  G. van Ommen,et al.  Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[15]  S. Bhatnagar,et al.  Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. , 2009, Human molecular genetics.

[16]  Giulio Cossu,et al.  Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs , 2006, Nature.

[17]  G. van Ommen,et al.  In vivo comparison of 2′‐O‐methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping , 2009, The journal of gene medicine.

[18]  D. Duan,et al.  Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. , 2009, The Journal of clinical investigation.

[19]  I. Graham,et al.  Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  H. Sweeney,et al.  Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of duchenne muscular dystrophy , 2010, Muscle & nerve.

[21]  R. Ahima,et al.  Functional improvement of dystrophic muscle by myostatin blockade , 2002, Nature.

[22]  G. V. Ommen,et al.  Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD) , 2011, Neuromuscular Disorders.

[23]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.

[24]  F. Muntoni,et al.  194th ENMC international workshop. 3rd ENMC workshop on exon skipping: Towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8–10 December 2012, Naarden, The Netherlands , 2013, Neuromuscular Disorders.

[25]  F. Tsai,et al.  IGF-II and MMP9 as surgical repair indicators of ventricular septal defects. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[26]  M. Williams,et al.  Seasonal variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor of matrix metalloproteinase-1 with storage at -80°C. , 2011, Clinical biochemistry.

[27]  S. Dimmeler,et al.  EMBO Molecular Medicine: Fast Forward , 2014, EMBO molecular medicine.

[28]  C. Gutenbrunner.  CIRCADIAN VARIATIONS OF THE SERUM CREATINE KINASE LEVEL—A MASKING EFFECT? , 2000, Chronobiology international.

[29]  P. Spitali,et al.  Splice Modulating Therapies for Human Disease , 2012, Cell.

[30]  Kristy Brown,et al.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. , 2014, Human molecular genetics.

[31]  Kevin M Flanigan,et al.  The Muscular Dystrophies , 1999, Seminars in Neurology.

[32]  P. L. Puri,et al.  Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases , 2011, Molecular medicine.

[33]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[34]  R. Holder,et al.  Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer , 2013, British Journal of Cancer.

[35]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[36]  Xìao-chun Xu,et al.  Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer , 2008, International journal of cancer.

[37]  J. Mendell,et al.  Gentamicin‐induced readthrough of stop codons in duchenne muscular dystrophy , 2010, Annals of neurology.

[38]  Juliet A. Ellis,et al.  International Workshop : Newborn screening for Duchenne muscular dystrophy 14 – 16 th December , 2012 , Naarden , The Netherlands , 2013 .

[39]  K. Davies,et al.  Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches , 2013, Nature Reviews Genetics.

[40]  Jay J. Han,et al.  The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.

[41]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[42]  A. Krieg,et al.  FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga , 2017, Nucleic acid therapeutics.

[43]  Yuji Ogura,et al.  Matrix Metalloproteinase-9 Inhibition Improves Proliferation and Engraftment of Myogenic Cells in Dystrophic Muscle of mdx Mice , 2013, PloS one.

[44]  J. Verschuuren,et al.  Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy , 2013, Journal of Neurology, Neurosurgery & Psychiatry.